Simple Summary Immunotherapy has demonstrated the ability to reduce the risk of
recurrence for melanoma following surgical resection and improve survival in patients with …

Circulating cell-free tumor DNA (ctDNA) can serve as a real-time biomarker of tumor burden
and provide unique insights into the evolving molecular landscape of cancers under the …

Patients with resected stage IIB/C melanoma have high recurrence risk, similar to those with
resected stage IIIA/B disease. The phase 3, double-blind CheckMate 76K trial assessed 790 …

PURPOSE Effective treatments are needed for melanoma that progresses on inhibitors of
programmed cell death protein-1 (PD-1) or its ligand (PD-L1). We conducted the phase II …

PURPOSE To provide guidance to clinicians regarding the use of systemic therapy for
melanoma. METHODS American Society of Clinical Oncology convened an Expert Panel …

Immunotherapy has become the central pillar of cancer therapy. Immune checkpoint
inhibitors (ICIs), a major category of tumor immunotherapy, reactivate preexisting anticancer …

The role of neoadjuvant therapy is undergoing an historic shift in oncology. The emergence
of potent immunostimulatory anticancer agents has transformed neoadjuvant therapy from a …

Background Recent advances in digital pathology have enabled accurate and standardised
enumeration of tumour-infiltrating lymphocytes (TILs). Here, we aim to evaluate TILs as a …

Metastasis to lymph nodes (LNs) is a common feature of disease progression in most solid
organ malignancies. Consequently, LN biopsy and lymphadenectomy are common clinical …

Background Adjuvant treatments with PD-1 and BRAF+ MEK inhibitors statistically
significantly prolong recurrence-free survival in stage III cutaneous melanoma. Yet, the effect …